Clinical Trial Outcomes In EMPA-REG, empagliflozin users lost 23 kg over 2452 weeks
DES(1-3) IGF-1 is not separately enumerated on the WADA Prohibited List as of the 2026 iteration, although the WADA S2 category includes language covering "any substance with similar chemical structure or similar biological effect(s)," which would encompass IGF-1 analogues broadly
(2004), Nature***, reporting T4-driven cardiac progenitor migration, capillary formation, and improved functional outcomes after experimental myocardial infarction in mice
The reason is that drugs deliver synthetic appetite-suppressing chemical messengers like GLP-1, GIP, and glucagon agonists at levels astronomically higher than normally produced by the body
They not only control blood sugar but also reduce appetite, promote weight loss, and minimize the risk of hypoglycemia
GLP-1 is a synthetic peptide analog of glucagon-like peptide-1 that is widely studied in biochemical and physiological research
